MedTrace Logo

Evaluation of Biodentine Versus Glass Ionomer Cement in Treatment of Very Deep Carious Lesions

NCT02868918 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-09-15

No results posted yet for this study

Summary

The aim of this study is to compare the effect of new bioactive dentine substitute (Biodentine) versus glass ionomer cement in very deep carious lesions clinically and radiographically using digital radiography in the terms of postoperative pain and biocompatibility to the pulp.

Conditions

  • Deep Caries

Interventions

DRUG

biodentine

tricalcium silicate cement used to replace the carious dentin

DRUG

glass ionomer cement

high viscosity glass ionomer used as a base material

DEVICE

DigoraH optium

digital Xray for follow up

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Ahmed Elkhadem, PhD · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-01
Primary Completion
2019-01-01
Completion
2019-03-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02868918 on ClinicalTrials.gov